Мы используем файлы cookie.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
Dermatologic drugs
PDC-APB
Другие языки:

    PDC-APB

    Подписчиков: 0, рейтинг: 0

    PDC-APB
    PDC-APB.svg
    Clinical data
    Other names 3-Pentadecyl-1,2-phenylene bis(4-(4-aminophenyl)butanoate; Benzenebutanoic acid, 4-amino-, 1,1'-(3-pentadecyl-1,2-phenylene) ester
    Identifiers
    • [2-[4-(4-aminophenyl)butanoyloxy]-3-pentadecylphenyl] 4-(4-aminophenyl)butanoate
    CAS Number
    PubChem CID
    UNII
    Chemical and physical data
    Formula C41H58N2O4
    Molar mass 642.925 g·mol−1
    3D model (JSmol)
    • CCCCCCCCCCCCCCCC1=C(C(=CC=C1)OC(=O)CCCC2=CC=C(C=C2)N)OC(=O)CCCC3=CC=C(C=C3)N
    • InChI=1S/C41H58N2O4/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-20-35-21-17-22-38(46-39(44)23-15-18-33-25-29-36(42)30-26-33)41(35)47-40(45)24-16-19-34-27-31-37(43)32-28-34/h17,21-22,25-32H,2-16,18-20,23-24,42-43H2,1H3
    • Key:VLRZIRYGLUVGGU-UHFFFAOYSA-N

    PDC-APB, or 3-pentadecyl-1,2-phenylene bis(4-(4-aminophenyl)butanoate), is a drug candidate under evaluation to determine if it might protect against contact dermatitis caused by urishiol from poison ivy, poison oak, and poison sumac.

    History

    The compound is one of a class of compounds developed through University of Mississippi research by Mahmoud ElSohly, Waseem Gul, and Mohammad Khalid Ashfaq. Work on the compound is ongoing under Hapten Sciences, who licensed the university's research in 2010.

    Evaluation as a drug candidate

    The compound has been evaluated in two Phase I clinical trials, and a third Phase I randomized controlled trial, with a secondary objective of evaluating the effect of treatment on urishiol sensitivity, is due to be completed in December 2022.

    See also


    Новое сообщение